Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654193 · ClinicalTrials.gov registry record · Phase 1
Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
A Phase 1 study of Acute Kidney Injury, sponsored by Hope Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 3
- Study locations
NCT06654193: Recruiting Phase 1 study of Acute Kidney Injury, sponsored by Hope Biosciences.
NCT06654193 is a Phase 1 study of Acute Kidney Injury that is actively recruiting participants, run by Hope Biosciences. The registered enrollment target is 70 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654193, a Phase 1 study of Acute Kidney Injury, is actively recruiting participants, sponsored by Hope Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
Primary Outcome
Incidence of treatment-related adverse events (TEAEs) will be monitored to assess the safety of the infusion product on the patients in Phase 1 of the trial.
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG Allogeneic HB-adMSCs
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Francisco - San Francisco
Texas
- University of Texas Health Science Center at Houston (UTHealth Houston) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 1 |
What NCT06654193 shows while recruiting
NCT06654193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT06654193 reports a single indexed study location in Alabama, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06654193 about?
NCT06654193 is a clinical study titled "Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury". This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
What is the current status of trial NCT06654193?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2026-02-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06654193 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06654193?
The interventions under investigation include: Normal Saline (DRUG), Allogeneic HB-adMSCs (DRUG).
Who is sponsoring clinical trial NCT06654193?
This trial is sponsored by Hope Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06654193 being conducted?
This trial has 3 study locations across Alabama, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06654193's enrollment target sits among peer trials
70 49th of 74 higher than 25 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
COMPLETED · Phase 1
-
Ibuprofen and Biomarkers of Acute Kidney Injury After Running in the Heat
COMPLETED · Phase 1
-
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
COMPLETED · Phase 1
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI